TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07523542: A Phase 1/2, Open-Label, Biomarker-Guided, Non-Randomized, Multicenter Study of Autologous CAR-T Cell Therapy Targeting CD19 or BCMA in Adults With Refractory Systemic Lupus Erythematosus With or Without Active Lupus Nep

Sponsor: Beijing Biotech · Phase: PHASE1/PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 24 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$9,384,000

Rescue Site Savings

+$6,187,575

Unlock Full NCT07523542 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07523542 Rescue Dossier →